Skip to main content
Top
Published in: Familial Cancer 4/2010

01-12-2010

Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation

Authors: Israel Gomy, Greice Andreotti Molfetta, Ester de Andrade Barreto, Cristiane Ayres Ferreira, Dalila Luciola Zanette, José Cláudio Casali-da-Rocha, Wilson Araujo Silva Jr.

Published in: Familial Cancer | Issue 4/2010

Login to get access

Abstract

von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary cancer syndrome that predisposes to the development of a variety of benign and malignant tumours, especially cerebellar haemangioblastomas, retinal angiomas and clear-cell renal cell carcinomas (RCC). The etiology and manifestations are due to germline and somatic mutations in the VHL tumour suppressor gene. VHL disease is classified into type 1 and type 2, showing a clear genotype-phenotype correlation, as type 2 is associated with phaeochromocytoma and essentially caused by missense mutations. The aim of this study is to characterize the phenotype and genotype of families with VHL disease. Eighteen of twenty patients from ten unrelated families underwent genetic testing, nine of them fulfilled VHL disease criteria and one had an apparently sporadic cerebellar haemangioblastoma. Four different germline mutations in the VHL gene were identified: c.226_228delTTC (p.Phe76del); c.217C > T (p.Gln73X); IVS1-1 G > A and IVS2-1 G > C. The first three mutations were associated with type 1 disease and the last one with type 2B, which had never been identified in the germline. The transcriptional processing of a novel splice-site mutation was characterised. Three type 1 VHL families showed large deletions of the VHL gene, two of them encompassed the FANCD2/C3orf10 genes and were not associated with renal lesions. We also suggest that such families should be subclassified according to the risk of RCC and the extent of the VHL gene deletions. This study highlights the need for a through clinical and molecular characterisation of families with VHL disease to better delineate its genotype-phenotype correlation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Maher ER, Kaelin WG (1997) von Hippel-Lindau disease. Medicine (Baltimore) 76:381–391CrossRef Maher ER, Kaelin WG (1997) von Hippel-Lindau disease. Medicine (Baltimore) 76:381–391CrossRef
2.
go back to reference Maher ER, Iselius L, Yates JR et al (1991) von Hippel-Lindau disease: a genetic study. J Med Genet 28:443–447CrossRefPubMed Maher ER, Iselius L, Yates JR et al (1991) von Hippel-Lindau disease: a genetic study. J Med Genet 28:443–447CrossRefPubMed
3.
go back to reference Knudson AGL (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823CrossRefPubMed Knudson AGL (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820–823CrossRefPubMed
4.
go back to reference Richards FM, Crossey PA, Phipps ME et al (1994) Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene. Hum Mol Genet 3:595–598CrossRefPubMed Richards FM, Crossey PA, Phipps ME et al (1994) Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene. Hum Mol Genet 3:595–598CrossRefPubMed
5.
go back to reference Gnarra JR, Tory K, Weng Y et al (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85–90CrossRefPubMed Gnarra JR, Tory K, Weng Y et al (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85–90CrossRefPubMed
6.
go back to reference Maxwell PH, Wiesener MS, Chang GW et al (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271–275CrossRefPubMed Maxwell PH, Wiesener MS, Chang GW et al (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271–275CrossRefPubMed
7.
go back to reference Crossey PA, Richards FM, Foster K et al (1994) Identification of intragenic mutations in the von Hippel-Lindau tumor suppressor gene and correlations with disease phenotype. Hum Mol Genet 3:1303–1308CrossRefPubMed Crossey PA, Richards FM, Foster K et al (1994) Identification of intragenic mutations in the von Hippel-Lindau tumor suppressor gene and correlations with disease phenotype. Hum Mol Genet 3:1303–1308CrossRefPubMed
8.
go back to reference Maher ER, Webster AR, Richards FM et al (1996) Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet 33:328–332CrossRefPubMed Maher ER, Webster AR, Richards FM et al (1996) Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet 33:328–332CrossRefPubMed
9.
go back to reference Stolle C, Glenn G, Zbar B et al (1998) Improved detection of germline mutations in the von Hippel-Lindau tumor suppressor gene. Hum Mutat 12:417–423CrossRefPubMed Stolle C, Glenn G, Zbar B et al (1998) Improved detection of germline mutations in the von Hippel-Lindau tumor suppressor gene. Hum Mutat 12:417–423CrossRefPubMed
10.
go back to reference Hoebeeck J, van der Luijt RB, Poppe B et al (2005) Rapid detection of VHL exon deletions using real-time quantitative PCR. Lab Invest 85:24–33PubMed Hoebeeck J, van der Luijt RB, Poppe B et al (2005) Rapid detection of VHL exon deletions using real-time quantitative PCR. Lab Invest 85:24–33PubMed
11.
go back to reference Hattori K, Teranishi J, Stolle C et al (2006) Detection of germline deletions using real-time quantitative polymerase chain reaction in Japanese patients with von Hippel-Lindau disease. Cancer Sci 97:400–405CrossRefPubMed Hattori K, Teranishi J, Stolle C et al (2006) Detection of germline deletions using real-time quantitative polymerase chain reaction in Japanese patients with von Hippel-Lindau disease. Cancer Sci 97:400–405CrossRefPubMed
12.
go back to reference Hes FJ, van der Luijt RB, Janssen ALW et al (2007) Frequency of von Hippel-Lindau germline mutations in classic and non-classic von Hippel-Lindau disease identified by DNA sequenciang Southern blot analysis and multiplex ligation-dependent probe amplification. Clin Genet 72:122–129CrossRefPubMed Hes FJ, van der Luijt RB, Janssen ALW et al (2007) Frequency of von Hippel-Lindau germline mutations in classic and non-classic von Hippel-Lindau disease identified by DNA sequenciang Southern blot analysis and multiplex ligation-dependent probe amplification. Clin Genet 72:122–129CrossRefPubMed
13.
go back to reference Chen F, Kishida T, Yao M et al (1995) Germline mutations in von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5:66–75CrossRefPubMed Chen F, Kishida T, Yao M et al (1995) Germline mutations in von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5:66–75CrossRefPubMed
14.
go back to reference Zbar B, Kishida T, Chen F et al (1996) Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe and Japan. Hum Mutat 8:348–357CrossRefPubMed Zbar B, Kishida T, Chen F et al (1996) Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe and Japan. Hum Mutat 8:348–357CrossRefPubMed
15.
go back to reference Mc Neill A, Rattenberry E, Barber R et al (2009) Genotype-phenotype correlations in VHL exon deletions. Am J Med Genet Part A 149A:2147–2151CrossRef Mc Neill A, Rattenberry E, Barber R et al (2009) Genotype-phenotype correlations in VHL exon deletions. Am J Med Genet Part A 149A:2147–2151CrossRef
16.
go back to reference Cascón A, Escobar B, Montero-Conde C et al (2007) Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. Hum Mutat 28:613–621CrossRefPubMed Cascón A, Escobar B, Montero-Conde C et al (2007) Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patients. Hum Mutat 28:613–621CrossRefPubMed
17.
go back to reference Franke G, Bausch B, Hoffmann M et al (2009) Alu-Alu recombination underlies the vast majority of large VHL germline deletions: molecular characterization and genotype-phenotype correlations in VHL patients. Hum Mutat 30:776–786CrossRefPubMed Franke G, Bausch B, Hoffmann M et al (2009) Alu-Alu recombination underlies the vast majority of large VHL germline deletions: molecular characterization and genotype-phenotype correlations in VHL patients. Hum Mutat 30:776–786CrossRefPubMed
18.
go back to reference Ong KR, Woodward ER, Killick P et al (2007) Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 28:143–149CrossRefPubMed Ong KR, Woodward ER, Killick P et al (2007) Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 28:143–149CrossRefPubMed
19.
go back to reference Rocha JC, Silva RL, Mendonça BB et al (2003) High frequency of novel germline mutations in the VHL gene in the heterogeneous population of Brazil. J Med Genet 40:e31CrossRefPubMed Rocha JC, Silva RL, Mendonça BB et al (2003) High frequency of novel germline mutations in the VHL gene in the heterogeneous population of Brazil. J Med Genet 40:e31CrossRefPubMed
20.
go back to reference American Society of Clinical Oncology (2003) Policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21:1–10CrossRef American Society of Clinical Oncology (2003) Policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21:1–10CrossRef
21.
go back to reference Gallou C, Chauveau D, Richard S et al (2004) Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. Hum Mutat 24:215–224CrossRefPubMed Gallou C, Chauveau D, Richard S et al (2004) Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. Hum Mutat 24:215–224CrossRefPubMed
22.
go back to reference Oberstrass J, Reifenberger G, Reifenberger J et al (1996) Mutation of the von Hippel-Lindau tumour suppressor gene in capillary hemangioblastomas of the central nervous system. J Pathol 179:151–156CrossRefPubMed Oberstrass J, Reifenberger G, Reifenberger J et al (1996) Mutation of the von Hippel-Lindau tumour suppressor gene in capillary hemangioblastomas of the central nervous system. J Pathol 179:151–156CrossRefPubMed
23.
go back to reference Olschwang S, Richard S, Boisson C et al (1998) Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. Hum Mutat 12:424–430CrossRefPubMed Olschwang S, Richard S, Boisson C et al (1998) Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. Hum Mutat 12:424–430CrossRefPubMed
28.
go back to reference Hes FJ, McKee S, Taphoorn MJ et al (2000) Cryptic von Hippel-Lindau disease: germline mutations in patients with hemangioblastoma only. J Med Genet 37:939–943CrossRefPubMed Hes FJ, McKee S, Taphoorn MJ et al (2000) Cryptic von Hippel-Lindau disease: germline mutations in patients with hemangioblastoma only. J Med Genet 37:939–943CrossRefPubMed
Metadata
Title
Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation
Authors
Israel Gomy
Greice Andreotti Molfetta
Ester de Andrade Barreto
Cristiane Ayres Ferreira
Dalila Luciola Zanette
José Cláudio Casali-da-Rocha
Wilson Araujo Silva Jr.
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2010
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9357-2

Other articles of this Issue 4/2010

Familial Cancer 4/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine